Soluble form of carbonic anhydrase IX (S-CA IX), assays to detect s-CA IX, CA IX'S coexpression with HER-2/NEU/C-ERBB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes
View Patent ↗Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons. Diagnostic/prognostic methods for precancer/cancer that detect or detect and quantitate s-CA IX in body fluids, are described. Also disclosed is the coexpression of CA IX and HER-2 that provides potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer/cancer. Further disclosed are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, useful diagnostically/prognostically and therapeutically for cancer/precancer. Preferred are new antibodies, specific for non-immunodominant epitopes of MN/CA IX, useful to detect soluble CA IX (s-CA IX) in body fluids, preferably in combination with antibodies specific to immunodominant epitopes of MN/CA IX.
1. A soluble form of CA IX which is released from cancerous or precancerous and cancerous cells of a vertebrate into a body fluid;
wherein said soluble form of CA IX is a protein having an amino acid sequence from or of SEQ ID NO: 5, or a protein having an amino acid sequence from or of CA IX's extracellular domain, wherein CA IX is encoded by a nucleotide sequence selected from:
i) SEQ ID NO: 1;
ii) nucleotide sequences which hybridize under stringent hybridization conditions of 0.02 M to 0.15 M NaCl at temperatures of 50° C. to 70° C. to the complement of SEQ ID NO: 1; and
iii) nucleotide sequences that differ from SEQ ID NO: 1 due to the degeneracy of the genetic code;
wherein said soluble CA IX has a molecular weight of from about 15 kilodaltons to about 54 kilodaltons (kd); and
wherein said precancerous and/or cancerous cells are from a precancer and/or cancer that is associated with abnormal expression of CA IX; and
wherein said soluble CA IX is specifically bound by the V/10 monoclonal antibody that is secreted from the hybridoma V/10-VU, which was deposited under the Budapest Treaty at the International Depository Authority of the Belgian Coordinated Collection of Microorganisms (BCCM) at the Laboratorium voor Moleculaire Bioloqie-Plasmidencollectie (LMBP) at the Universeit Gent in Gent, Belgium, under Accession No. LMBP 6009CB.
2. The soluble form of CA IX of claim 1 that has a molecular weight of about 50 to 54 kd.
3. The soluble form of CA IX according to claim 1 that is specifically bound by the M75 monoclonal antibody that is secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128.
4. The soluble form of CA IX according to claim 1 wherein said vertebrate cells are mammalian cells.
5. The soluble form of CA IX according to claim 1 wherein said vertebrate cells are human cells.
6. The soluble form of CA IX of claim 1 wherein said body fluid is selected from the group consisting of blood, serum, plasma, semen, breast exudate, saliva, tears, sputum, mucous, urine, gastric secretions, fecal suspensions, bile, lymph, ascites, pleural effusions, amniotic fluid, bladder washes, bronchioalveolar lavages and cerebrospinal fluid.
7. The soluble form of CA IX of claim 1 , which comprises the proteoglycan-like (PG) and carbonic anhydrase (CA) domains of CA IX.
8. The soluble form of CA IX of claim 1 , which comprises the carbonic anhydrase (CA) domain of CA 1× or parts of said CA domain.
9. The soluble form of CA IX of claim 1 wherein said precancer and/or cancer is associated with hypoxia.
10. The soluble form of CA IX of claim 1 wherein said precancer and/or cancer is of a tissue that is selected from the group consisting of mammary, urinary tract, kidney, ovarian, uterine, bladder, cervical, endometrial, vaginal, vulvar, prostate, liver, lung, skin, thyroid, pancreatic, testicular, brain, head and neck, gastrointestinal, colon, rectal, urethral and mesodermal tissues.
11. The soluble form of CA IX of claim 1 wherein said precancer and/or cancer is of a tissue selected from the group consisting of mammary, urinary tract, colon, rectal, kidney, bladder, urethral, and prostate tissues.
12. The soluble form of CA IX of claim 1 wherein said cancer is selected from the group consisting of breast, renal cell, uterine, cervical, colon, colorectal, esophageal, lung, and head and neck carcinomas.
13. The soluble form of CA IX of claim 1 wherein said cancer is selected from the group consisting of breast cancer, uterine cervical cancer, non-small cell lung cancer, head and neck cancer, renal cell carcinoma, and colorectal cancer.
14. The soluble form of CA IX of claim 1 wherein said cancer is metastatic breast cancer or renal cell carcinoma.
15. The soluble form of CA IX of claim 1 wherein said soluble CA IX has a molecular weight of from about 20 kd to about 54 kd.
16. The soluble form of CA IX of claim 1 which has a molecular weight of either about 50 kd or about 54 kd as approximated by Western Blotting.